Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable haemophilus influenzae protein D conjugate vaccine coadministered with DTPW-HBV/HIB and poliovirus vaccines

Pediatric Infectious Disease Journal

Volumn 30, Issue 1, 2011, Pages 69-72

  Bermal, Nancy ^a   Szenborn, Leszek ^b   Alberto, Edison ^a   Hernandez, Marina ^a   Pejcz, Jerzy ^c   Majda Stanislawska, Ewa ^d   Gatchalian, Salvacion ^e,f   Fanic, Aurélie ^g   Dieussaert, Ilse ^g   Schuerman, Lode ^g  

^a Research Institute for Tropical Medicine   (United States)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c Department of Paediatrics   (Poland)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e GLAXOSMITHKLINE   (United States)

^f UNIVERSITY OF THE PHILIPPINES MANILA   (Philippines)

^g GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

booster vaccination; immunogenicity; pneumococcal conjugate vaccine; safety

Indexed keywords

7 VALENT PNEUMOCOCCAL CONJUGATE VACCINE; 7VCRM; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; ORAL POLIOMYELITIS VACCINE; PHID-CV; PNEUMOCOCCAL NONTYPEABLE HAEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLIORIX; UNCLASSIFIED DRUG;

APPETITE; ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; DROWSINESS; DRUG SAFETY; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE SWELLING; IRRITABILITY; MAJOR CLINICAL STUDY; PAIN; PHARYNGITIS; PRIORITY JOURNAL; SEROTYPE; SIDE EFFECT; SWELLING; VACCINATION;

EID: 78650769788     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181f2da06     Document Type: Article

References (9)

1. Bermal N, Szenborn L, Chrobot A, et al. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity. Pediatr Infect Dis J. 2009;28(suppl):S89-S96.
2. Chevallier B, Vesikari T, Brzostek J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J. 2009;28(suppl):S109-S118.
3. Prymula R, Plisek S. Clinical experience with DTPw-HBV and DTPw-HBV/ Hib combination vaccines. Expert Opin Biol Ther. 2008;8:503-513.
4. Phillips KF. A new test of non-inferiority for anti-infective trials. Stat Med. 2003;22:201-212.
5. Knuf M, Szenborn L, Moro M, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J. 2009;28(suppl):S97-S108.
6. World Health Organization. Pertussis vaccines WHO position paper. Wkly Epidemiol Rec. 2005;80:31-39.
7. Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J. 2009;28(suppl):S66-S76.
8. Wysocki J, Tejedor JC, Grunert D, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different Neisseria meningi-tidis serogroup C conjugate vaccines. Pediatr Infect Dis J. 2009;28(suppl): S77-S88.
9. Vesikari T, Karvonen A, Lindblad N, et al. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal NTHi protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months. Pediatr Infect Dis J. 2010;29:e47-e56.